Patents by Inventor Christopher L. Reyes

Christopher L. Reyes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody and checkpoint inhibitor combination therapy
    Patent number: 11655304
    Abstract: The present invention provides a combination therapy for treatment of a tumour in a subject. The combination therapy comprises administration of (i) an antibody directed against cancer stem cells and (ii) a checkpoint inhibitor.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: May 23, 2023
    Assignee: Bionomics Limited
    Inventors: Tina Christine Lavranos, Daniel John Inglis, Christopher L. Reyes
  • Method of treating cancer by administering an anti-LGR5 monoclonal antibody
    Patent number: 10745487
    Abstract: The present invention relates generally to the field of cancer biology. Some embodiments of the methods and compositions provided herein relate to administration of humanized antibodies or antigen-binding fragments thereof that specifically bind to LRG5 to treat certain cancers.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: August 18, 2020
    Assignee: BIONOMICS LIMITED
    Inventors: Christopher L. Reyes, Peter Chu, Elizabeth Doolin, Jose Iglesias
  • ANTIBODY DRUG CONJUGATES THAT BIND LGR5
    Publication number: 20200114017
    Abstract: Embodiments of the methods and compositions provided herein relate to antibody drug conjugates comprising an antibody or antigen binding fragment thereof that specifically binds to human LGR5 in which the antibody or antigen binding fragment thereof is conjugated to a therapeutic agent, such as a drug, via a linker. Some embodiments relate to methods of treatment using such antibody drug conjugates, and methods of preparing such antibody drug conjugates.
    Type: Application
    Filed: June 16, 2017
    Publication date: April 16, 2020
    Inventors: Christopher L. Reyes, Peter Chu
  • Methods of blocking cancer stem cell growth
    Patent number: 10598653
    Abstract: Disclosed herein are antibodies against GPR49 and uses of such antibodies. The antibodies can be monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of blocking cancer stem cell growth with such antibodies.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: March 24, 2020
    Assignee: BIONOMICS INC.
    Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Weixing Yang, Christilyn Graff
  • HUMANIZED ANTIBODIES THAT BIND LGR5
    Publication number: 20190389964
    Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.
    Type: Application
    Filed: June 21, 2019
    Publication date: December 26, 2019
    Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
  • ANTIBODY AND CHECKPOINT INHIBITOR COMBINATION THERAPY
    Publication number: 20190263925
    Abstract: The present invention provides a combination therapy for treatment of a tumour in a subject. The combination therapy comprises administration of (i) an antibody directed against cancer stem cells and (ii) a checkpoint inhibitor.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 29, 2019
    Inventors: Tina Christine LAVRANOS, Daniel John INGLIS, Christopher L. REYES
  • Humanized antibodies that bind LGR5
    Patent number: 10358500
    Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: July 23, 2019
    Assignee: BIONOMICS INC.
    Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
  • ADMINISTRATION OF AN ANTI-LGR5 MONOCLONAL ANTIBODY
    Publication number: 20190100600
    Abstract: The present invention relates generally to the field of cancer biology.
    Type: Application
    Filed: March 21, 2017
    Publication date: April 4, 2019
    Inventors: Christopher L. Reyes, Peter Chu, Elizabeth Doolin, Jose Iglesias
  • Methods of inhibiting growth of a colon cancer tumor in a subject by administering monoclonal antibodies to G protein-coupled receptor 49 (GPR49)
    Patent number: 10196442
    Abstract: Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of treating cancer with such antibodies.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 5, 2019
    Assignee: Bionomics Inc.
    Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Christilyn Graff, Weixing Yang
  • HUMANIZED ANTIBODIES THAT BIND LGR5
    Publication number: 20170114145
    Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.
    Type: Application
    Filed: December 14, 2016
    Publication date: April 27, 2017
    Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
  • Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors
    Patent number: 9631024
    Abstract: Disclosed herein are anti-LGR4 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR4 without disrupting LGR4-RSPO1 binding or signaling, and may disrupt LGR4 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for antibodies that bind LGR4, for example without disrupting LGR4-RSPO binding or signaling.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: April 25, 2017
    Assignee: Bionomics, Inc.
    Inventors: Christopher L. Reyes, Kristen M. Smith, Peter Chu, Lioudmila A. Campbell, Eric Ailor
  • Humanized antibodies that bind LGR5
    Patent number: 9546214
    Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: January 17, 2017
    Assignee: Bionomics, Inc.
    Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
  • ANTIBODIES AND METHODS OF TREATING CANCER
    Publication number: 20160159903
    Abstract: Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of treating cancer with such antibodies.
    Type: Application
    Filed: December 11, 2015
    Publication date: June 9, 2016
    Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Christilyn Graff, Weixing Yang
  • ANTIBODIES THAT BIND LGR4
    Publication number: 20160046723
    Abstract: Disclosed herein are anti-LGR4 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR4 without disrupting LGR4-RSPO1 binding or signaling, and may disrupt LGR4 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for antibodies that bind LGR4, for example without disrupting LGR4-RSPO binding or signaling.
    Type: Application
    Filed: June 17, 2015
    Publication date: February 18, 2016
    Inventors: Christopher L. Reyes, Kristen M. Smith, Peter Chu, Lioudmila A. Campbell, Eric Ailor
  • HUMANIZED ANTIBODIES THAT BIND LGR5
    Publication number: 20160031984
    Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.
    Type: Application
    Filed: April 2, 2015
    Publication date: February 4, 2016
    Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
  • Methods of treating cancer by administering anti-GPR49 antibodies
    Patent number: 9220774
    Abstract: Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: December 29, 2015
    Assignee: Bionomics Inc.
    Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Weixing Yang, Christilyn Graff
  • Methods of inhibiting solid tumor growth by administering GPR49 antibodies
    Patent number: 9221906
    Abstract: Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of treating cancer with such antibodies.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: December 29, 2015
    Assignee: Bionomics Inc.
    Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Christilyn Graff, Weixing Yang
  • Anti-GPR49 monoclonal antibodies
    Patent number: 9221907
    Abstract: Described herein are to antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: December 29, 2015
    Assignee: Bionomics Inc.
    Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Weixing Yang, Christilyn Graff
  • ANTIBODIES AND METHODS OF TREATING CANCER
    Publication number: 20150037324
    Abstract: Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of treating cancer with such antibodies.
    Type: Application
    Filed: October 31, 2012
    Publication date: February 5, 2015
    Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Christilyn Graff, Weixing Yang
  • ANTI-GPR49 ANTIBODIES
    Publication number: 20140302054
    Abstract: Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies.
    Type: Application
    Filed: October 31, 2012
    Publication date: October 9, 2014
    Inventors: Christopher L. Reyes, Peter Chu, Xiangyang Tan, Weixing Yang, Christilyn Graff